Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 106 AL 120

Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents

Darvesh AS, Carroll RT, Bishayee A, Geldenhuys WJ, Van der Schyf CJ.

Expert Rev Neurother. 2010 May;10(5):729-45. doi: 10.1586/ern.10.42.

Alzheimer's disease: strategies for disease modification

Citron M.

Nat Rev Drug Discov. 2010 May;9(5):387-98. doi: 10.1038/nrd2896.

Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks

de Mendonça A, Cunha RA.

J Alzheimers Dis. 2010;20 Suppl 1:S249-52. doi: 10.3233/JAD-2010-01411.

Targeting tau protein in Alzheimer's disease

Gong CX, Grundke-Iqbal I, Iqbal K.

Drugs Aging. 2010 May;27(5):351-65. doi: 10.2165/11536110-000000000-00000.

Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease

McGeown WJ, Shanks MF, Forbes-McKay KE, Waiter GD, Elrick I, Venneri MG, Venneri A.

Curr Alzheimer Res. 2010 Aug;7(5):415-27. doi: 10.2174/156720510791383877.

Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface?

Larner AJ.

Int J Clin Pract. 2010 Apr;64(5):534-6. doi: 10.1111/j.1742-1241.2009.02305.x.

Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects

Müller WE, Eckert A, Kurz C, Eckert GP, Leuner K.

Mol Neurobiol. 2010 Jun;41(2-3):159-71. doi: 10.1007/s12035-010-8141-5. Epub 2010 May 12.

Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S.

Rejuvenation Res. 2010 Apr-Jun;13(2-3):301-13. doi: 10.1089/rej.2009.0993.

Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase

Atamna H, Kumar R.

J Alzheimers Dis. 2010;20 Suppl 2:S439-52. doi: 10.3233/JAD-2010-100414.

Rethinking Alzheimer's disease therapy: are mitochondria the key?

Ankarcrona M, Mangialasche F, Winblad B.

J Alzheimers Dis. 2010;20 Suppl 2:S579-90. doi: 10.3233/JAD-2010-100327.

A mitocentric view of Alzheimer's disease suggests multi-faceted treatments

Gibson GE, Shi Q.

J Alzheimers Dis. 2010;20 Suppl 2(0 2):S591-607. doi: 10.3233/JAD-2010-100336.

Murine models of Alzheimer's disease and their use in developing immunotherapies

Wisniewski T, Sigurdsson EM.

Biochim Biophys Acta. 2010 Oct;1802(10):847-59. doi: 10.1016/j.bbadis.2010.05.004. Epub 2010 May 13.

Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease

Daiello LA, Ott BR, Festa EK, Friedman M, Miller LA, Heindel WC.

J Clin Psychopharmacol. 2010 Jun;30(3):245-51. doi: 10.1097/JCP.0b013e3181da5406.

Validation of the Brazilian version of the quality of life scale for patients with Alzheimer's disease and their caregivers (QOL-AD)

Novelli MM, Nitrini R, Caramelli P.

Aging Ment Health. 2010 Jul;14(5):624-31. doi: 10.1080/13607861003588840.

Bapineuzumab

Kerchner GA, Boxer AL.

Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi: 10.1517/14712598.2010.493872.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias